Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (FREESIA-3)

Last Updated   May 14, 2025

Want to learn how to participate in this trial?

80202135FNAIT3003

OVERVIEW

  • Sexes Eligible for Study
    female
  • Age
    18+ years
  • Phase
    phase 3
  • Sites
    12 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

CONDITIONS

  • Thrombocytopenia, Neonatal Alloimmune

ELIGIBILITY


Inclusion Criteria:

* Pregnant and an estimated gestational age from week 13 to 18 at visit 1
* Has a history of greater than or equal to (>=) 1 prior pregnancy with FNAIT based on medical records including: a) neonatal platelet count less than (<) 150*10^9/Liter with no fetal/neonatal intracranial hemorrhage (ICH) or severe fetal/neonatal hemorrhage (standard-risk) OR b) fetus/neonate with ICH or severe hemorrhage in a fetus/neonate (high-risk)
* Current pregnancy with presence of maternal anti-HPA-1a and/or anti-HPA-5b alloantibody and positive fetal HPA-1a and/or HPA-5b genotype as confirmed by cell-free fetal DNA in maternal blood
* Health status considered stable by the investigator based on physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at screening
* For maternal participant and neonate/infant, willing to forego participation in another clinical study of an investigational therapy until the last follow-up visit


Exclusion Criteria:

* Currently pregnant with multiple gestations (twins or more)
* History of severe preeclampsia in a previous pregnancy
* History of myocardial infarction, unstable ischemic heart disease, or stroke
* Known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients, to IVIG or to prednisone
* Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant


Inclusion Criteria:

* Pregnant and an estimated gestational age from week 13 to 18 at visit 1
* Has a history of greater than or equal to (>=) 1 prior pregnancy with FNAIT based on medical records including: a) neonatal platelet count less than (<) 150*10^9/Liter with no fetal/ne

More...

DETAILS

LOCATIONS

Locations in:
Austria, Germany, Poland, United Kingdom
Country (4) City or Province (12) Status
Austria Graz Medizinische Universitaet Graz
RECRUITING
Germany Giessen Universitaetsklinikum Giessen und Marburg GmbH
RECRUITING
Poland Lodz Instytut Centrum Zdrowia Matki Polki
RECRUITING
Poland Warszawa Instytut Matki i Dziecka
RECRUITING
Poland Warszawa Panstwowy Instytut Medyczny MSWiA w Warszawie
RECRUITING
United Kingdom Birmingham Birmingham Women's Hospital
RECRUITING
United Kingdom Liverpool Liverpool Women's NHS Foundation Trust - Liverpool Women's Hospital
RECRUITING
Austria Vienna Medical University Vienna
RECRUITING
Germany Jena Universitatsklinikum Jena
RECRUITING
Germany Tuebingen Universitaetsklinikum Tuebingen
RECRUITING
United Kingdom London Queen Charlotte's and Chelsea Hospital
RECRUITING
United Kingdom Oxford John Radcliffe Hospital
RECRUITING
Show More
Geo Locations

47.06667, 15.45

50.58727, 8.67554

51.75, 19.46667

52.22977, 21.01178

52.22977, 21.01178

52.48142, -1.89983

53.41058, -2.97794

48.20849, 16.37208

50.92878, 11.5899

48.52266, 9.05222

51.50853, -0.12574

51.75222, -1.25596

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.